1. Home
  2. Products
  3. Customized ADCs
  4. KIRD2
  5. Anti-KIRD2 (lirilumab)-MC-MMAF ADC

Anti-KIRD2 (lirilumab)-MC-MMAF ADC (CAT#: ADC-W-2080)

This ADC product is comprised of an anti-KIRD2 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • KIRD2
  • Alternative Names
  • KIRD2
  • Overview
  • Human KIRD2 subgroup (killer cell Immunoglobulin-like Receptor subgroup, including KIR2DL1 (nkat1/CD158A), KIR2DL2 (nkat6/CD158B1), KIR2DL3 (nkat2/CD158B2), KIR2DS1 (CD158H) and KIR2DS2 -nkat5/CD158J-).
  • Overview
  • Human Anti-KIRD2 IgG4-kappa antibody, lirilumab
  • Generic name
  • lirilumab
  • Host animal
  • Human
  • Name
  • MC (maleimidocaproyl)
  • Description
  • Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
  • Name
  • MMAF
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-2080. Click the button above to contact us or submit your feedback about this product.

Quick Links

Other Products

Same Payload Same Target Same Linker
CAT# Product Name Linker Payload
ADC-W-2573 Anti-SLC34A2 (Lifastuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2550 Anti-CD74-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2622 Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2585 Anti-EGFR (Zalutumumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2612 Anti-MS4A1 (Rituximab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
CAT# Product Name Linker Payload
ADC-W-2083 Anti-KIRD2 (lirilumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2079 Anti-KIRD2 (lirilumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-2082 Anti-KIRD2 (lirilumab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-2081 Anti-KIRD2 (lirilumab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
ADC-W-2078 Anti-KIRD2 (lirilumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
CAT# Product Name Linker Payload
ADC-W-452 Anti-CD70 (clone 1F6)-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-2612 Anti-MS4A1 (Rituximab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-114 Anti-CD33 (clone m2H12)-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-115 Anti-CD33 (clone h2H12)-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-515 Anti-EGFR (ABT-806)-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.